FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * DARGAN CHARLES K 2. Issuer Name and Ticker or Trading Symbol BIOLARGO, INC. [ BLGO ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Financial Officer
(Last)         (First)         (Middle)
18851 NE 29TH AVENUE, SUITE 700		 3. Date of Earliest Transaction (MM/DD/YYYY)
10/8/2020
(Street)
AVENTURA, FL 3318
(City)       (State)       (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option to purchase common stock  $0.15  10/8/2020    A     2500      10/8/2020  9/30/2030  Common stock  2500  $0 (1) 3610786 (2) D   
Option to purchase common stock  $0.15  10/8/2020    A     50000      10/8/2020  9/30/2030  Common stock  50000  $0 (3) 3460786 (4) D   

Explanation of Responses:
(1)  This Option was granted to Reporting Person to replace options to purchase 10,000 shares of Issuer's common stock that had been issued approximately 10 years ago to compensate Reporting Person for services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and the Issuer's current stock price, pursuant to a plan adopted by the Issuer's Compensation Committee.
(2)  This amount reflects, in addition to the reported option grant, the expiration on September 30, 2020, of an option to purchase an 10,000 shares of common stock.
(3)  This Option was granted to Reporting Person to replace options to purchase 200,000 shares of Issuer's common stock that had been issued approximately 10 years ago to compensate Reporting Person for services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and the Issuer's current stock price, pursuant to a plan adopted by the Issuer's Compensation Committee.
(4)  This amount reflects, in addition to the reported option grant, the expiration on August 5, 2020, of an option to purchase an 200,000 shares of common stock.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
DARGAN CHARLES K
18851 NE 29TH AVENUE
SUITE 700
AVENTURA, FL 3318

Chief Financial Officer

Signatures
/s/ John R. Browning, Attorney-in-fact 10/8/2020
**Signature of Reporting Person Date
BioLargo (QB) (USOTC:BLGO)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more BioLargo (QB) Charts.
BioLargo (QB) (USOTC:BLGO)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more BioLargo (QB) Charts.